Independent Non-Executive Director
Skills and experience
Ms Olson brings a depth of experience in commercialisation and corporate strategy in oncology, including in the radiopharmaceutical sector, which our Board values highly as it oversees the implementation of Telix’s strategy.
Ms Olson received her MBA and BSB from the University of St. Thomas and BSB from the University of Minnesota.
Career summary
Ms Olson’s most recent executive role was with Cardinal Health, the largest provider of radiopharmaceuticals in the United States. As President of Cardinal Health Nuclear & Precision Health Solutions, overseeing Cardinal’s radiopharmaceutical manufacturing and nuclear pharmacy network, she led a significant business transformation that increased market share and profit growth. Prior to Cardinal Health, Ms Olson served as President of NaviMed, as Vice President Diagnostics at Eli Lilly and Company (from November 2009 to July 2011), and as President and Chief Executive Officer at Roche Diagnostics Corporation (from June 2005 to May 2008). Previously she was a Director at Asuragen, Inc (from August 2016 to March 2021) and BioTelemetry, Inc (from February 2019 to February 2021). She currently serves as a Director of Castle Biosciences, Inc (since April 2021), an Advisory Board member at Langham Logistics (since August 2021), a Director, at Education and Research Foundation, Nuclear Medicine & Molecular Imaging (since April 2022), a Partner at Trusted Health Advisors (since August 2023) and a Director of MiMedx Group, Inc. (since March 2024).
Committee memberships
- Audit and Risk Committee
- People Committee
- Nomination Committee